Should You Buy China Biologic Products Holdings Inc (CBPO) in Biotechnology Industry?

Tuesday, July 7, 2020 1:42 PM | InvestorsObserver Analysts

The 46 rating InvestorsObserver gives to China Biologic Products Holdings Inc (CBPO) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 32 percent of stocks in the Biotechnology industry, CBPO’s 46 overall rating means the stock scores better than 46 percent of all stocks.

Overall Score - 46
CBPO has an Overall Score of 46. Find out what this means to you and get the rest of the rankings on CBPO!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 46 would rank higher than 46 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With China Biologic Products Holdings Inc Stock Today?

China Biologic Products Holdings Inc (CBPO) stock has risen 1.83% while the S&P 500 is lower by -0.31% as of 1:39 PM on Tuesday, Jul 7. CBPO is up $1.94 from the previous closing price of $106.10 on volume of 79,217 shares. Over the past year the S&P 500 has gained 6.52% while CBPO is up 15.24%. CBPO earned $3.95 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 27.37.

To see InvestorsObserver's Sentiment Score for China Biologic Products Holdings Inc click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Middle East Stocks Mostly Rise, Saudi Shares Boosted by Oil Outlook

European ADRs Edge Lower in Monday Trading

Should You Buy Pacific Biosciences of California Inc (PACB) Stock on Monday?

Is Fennec Pharmaceuticals Inc (FENC) Stock About to Get Hot Monday?

Do Traders View Akers Biosciences Inc (AKER) Stock's Current Trend Positively?

Related Companies